The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Emergency Care Partners

Advised Emergency Care Partners (“ECP”), a leading provider of emergency department management services and its majority owner Varsity Healthcare Partners (“VHP”) on a growth recapitalization transaction, inclusive of a $100 million preferred equity investment led by MidOcean Partners (“MidOcean”)

Notified

Advising Equiniti Group, a Siris Capital Group portfolio company, on the acquisition of the Notified, a wholly owned subsidiary of West Technology Group., an Apollo Global Management portfolio company

Pacific Smiles Group

Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover

PRISM Vision Group

Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader

Brigit

Advised Upbound Group, a technology and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, on its acquisition of Brigit, a leading financial health technology company

Centogene GmbH

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases

Blue Owl Technology Finance Corp. II (“OTF II”)

Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF

Golub Capital LLC

Advising Mizuho Bank, Ltd., the banking arm of Mizuho Financial Group, Inc., on its purchase of a passive, non-voting minority stake in Golub Capital’s management companies

U.S. Operations of NextStream

Advised RadiusDC, a national owner and operator of highly-connected, urban-located data centers, on the acquistion of a series of entities comprising the U.S. operations of NextStream, a data center operator in Latin America owned by Actis

Medical Review Institute of America

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

U.S. Acute Care Solutions

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

illion Australia Pty Ltd

Advising Experian Plc, the world’s leading global information services company, on the acquisition of illion Australia Pty Ltd, one of Australasia's leading consumer and commercial credit bureaus

myHomecare Group

Advising Australian Unity on its acquisition of myHomecare Group

Exit of Homesafe Equity Release Joint Venture

Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture

Lucky Bucks, LLC

Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process

Slayback Pharma LLC

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

Clinigen Ltd’s portfolio of Established Medicines

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

Australian Unity Diversified Property Fund

Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund

Interest in Joint Venture with CarepathRx Health System Solutions

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

Clinigen Ltd’s Lamda Laboratories

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Gaming Services Division of Global Payments

Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm

Clinigen Ltd’s Proleukin

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

Kyowa Kirin International’s established medicines business

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company